News

0

DGAP-HV: MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 18.05.2022 in Planegg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

0

DGAP-HV: MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 18.05.2022 in Planegg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

0

Premier, Inc. to Report Fiscal 2022 Third-Quarter Results and Host Conference Call on May 3, 2022

Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2022 third quarter on Tuesday, May 3, 2022, at approximately 6:30 a.m. ET. The company will also

0

DGAP-News: Evotec SE to announce results for fiscal year 2021 on 12 April 2022

0

DGAP-News: Evotec SE: Bekanntgabe der Ergebnisse für das Geschäftsjahr 2021 am 12. April 2022

0

Acadia Healthcare Announces Christopher Hunter as New Chief Executive Officer

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that its Board of Directors has named Christopher Hunter as the Company’s new Chief Executive Officer. He will join Acadia on April

0

Novocure to Report First Quarter 2022 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2022 on Thursday, April 28, 2022, before the U.S. financial markets open. Novocure’s management

0

Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial

Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Oncology at the McKnight Brain Institute at the University of Florida, will present updated results from

0

LivaNova to Announce First-Quarter 2022 Results

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2022 results on Wednesday, May 4, 2022 at 1 p.m

0

Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer

Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 pivotal INNOVATE-3 study evaluating the safety and efficacy of Tumor Treating Fields

0

DGAP-News: MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL

0

DGAP-News: MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL

0

DGAP-News: MorphoSys und Incyte geben vorläufige Swissmedic-Zulassung von Minjuvi(R) (Tafasitamab) in Kombination mit Lenalidomid zur Behandlung von erwachsenen Patienten mit R/R DLBCL bekannt

0

DGAP-News: MorphoSys und Incyte geben vorläufige Swissmedic-Zulassung von Minjuvi(R) (Tafasitamab) in Kombination mit Lenalidomid zur Behandlung von erwachsenen Patienten mit R/R DLBCL bekannt

0

DGAP-News: Evotec erhält 3 Mio. €-Meilenstein für Bayers Start einer klinischen Phase-II-Studie mit DNP-Programm

0

DGAP-News: Evotec receives € 3 m milestone payment for Bayer starting Phase II clinical development of DNP programme

0

DGAP-News: MorphoSys AG veröffentlicht Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2021 und informiert über die aktuelle Unternehmensentwicklung

0

DGAP-News: MorphoSys AG veröffentlicht Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2021 und informiert über die aktuelle Unternehmensentwicklung

0

DGAP-News: MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

0

DGAP-News: MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

0

Southcoast Behavioral Health Expands Services and Capacity

Southcoast Behavioral Health today reinforced its strong commitment to the communities it serves through the addition of a dedicated child and adolescent behavioral health program, expanding the

0

DGAP-News: US-amerikanisches National Comprehensive Cancer Network(R) stuft Monjuvi(R) (Tafasitamab-cxix) in seinen Leitlinien als bevorzugte Behandlungsmethode für B-Zell-Lymphome ein

0

DGAP-News: National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas

0

DGAP-News: National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas